Residual C-peptide secretion is associated with better CGM-metrics in adults with short-lasting type 1 diabetes
Amendolara R, Zampetti S, Siena A, et al.
Diabetes Res Clin Pract. 2025:112006.
Leggi
Association between sarcopenia and weight-adjusted waist index in male patients with type 2 diabetes
Xiang Y, Wang Z, Xu J, et al.
BMC Endocr Disord. 2025;25(1):20.
Leggi
Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: a retrospective, real-world study
Gulati K, Wijndaele K, Webb J, et al.
Diabetes Obes Metab. Pub. online 22 Jan 2025.
Leggi
Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: real-world evidence from a 22-year follow-up study
Akerkar A, Rønn PF, Kosjerina V, et al.
Diabetes Obes Metab. Pub. online 22 Jan 2025.
Leggi
AIFA: Classificazione, in apposita sezione denominata classe C, del medicinale per uso umano a base di semaglutide «Rybelsus» 25 mg e 50 mg (Determina n. 788/2024)
20/01/2025
Leggi
Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes
Mueller J, Breeze P, Fusco F, et al.
Diabetologia. Pub. online 23 Jan 2025.
Leggi
Bariatric surgery and cardiovascular outcomes in patients with obesity, metabolic dysfunction-associated steatotic liver disease, and coronary artery disease: a population-based matched cohort study
Krishnan A, Sims OT, Teran D, et al.
Eur Heart J Qual Care Clin Outcomes. 2025:qcaf001.
Leggi
AIFA: Autorizzazione all’immissione in commercio del medicinale per uso umano, a base di Liraglutide, «Diavic», in apposita sezione denominata classe C
20/01/2025
Leggi
Barriers and new opportunities in developing effective therapies for diabetic neuropathy: international expert consensus recommendations
Brock C, Andersen H, Alibegovic AC, et al.
Diabetes Res Clin Pract. 2025:112010.
Leggi
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Davies MJ, van der Meer P, Verma S, Patel S, et al.
Lancet Diabetes Endocrinol. Pub. online 20 Jan 2025.
Leggi